David E. Lazar - 06 Feb 2025 SCHEDULE 13D Report for Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC)

Filing Manager
David E. Lazar
Reporting Manager
Lazar David E.
Security
Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value
Symbol
CYCC
Shares outstanding
246,345,833 shares
Disclosed Ownership
39,021,180 shares
Ownership
16%
Form type
SCHEDULE 13D
Filing time
28 Feb 2025, 16:46:36 UTC
Date of event
06 Feb 2025
Next filing
04 Aug 2025
SEC
View on sec.gov

Quoteable Key Fact

"David E. Lazar disclosed 16% ownership in Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC) on 06 Feb 2025."

Quick Takeaways

  • David E. Lazar filed SCHEDULE 13D for Cyclacel Pharmaceuticals, Inc. Common Stock, $0.001 par value (CYCC).
  • Disclosed ownership: 16%.
  • Date of event: 06 Feb 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 28 Feb 2025, 16:46.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Lazar David E. 16% 39,021,180 39,021,180 0 /s/ David E. Lazar David E. Lazar 0001932843
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .